FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 37,798 shares of FibroGen stock in a transaction that occurred on Thursday, January 12th. The stock was sold at an average price of $23.85, for a total transaction of $901,482.30. Following the completion of the sale, the chief executive officer now owns 3,298,100 shares of the company’s stock, valued at $78,659,685. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of FibroGen, Inc (NASDAQ:FGEN) opened at 25.50 on Friday. FibroGen, Inc has a 52 week low of $14.38 and a 52 week high of $25.65. The firm’s 50-day moving average is $21.66 and its 200 day moving average is $19.29. The firm’s market capitalization is $1.61 billion.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.21. The company had revenue of $30.10 million for the quarter, compared to analyst estimates of $24.30 million. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. On average, equities analysts forecast that FibroGen, Inc will post ($0.99) earnings per share for the current year.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

TRADEMARK VIOLATION WARNING: “FibroGen, Inc (FGEN) CEO Sells $901,482.30 in Stock” was first posted by Daily Political and is the propert of of Daily Political. If you are accessing this story on another publication, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at http://www.dailypolitical.com/2017/01/14/fibrogen-inc-fgen-ceo-sells-901482-30-in-stock.html.

A number of research firms recently commented on FGEN. Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Friday, November 11th. Leerink Swann restated a “buy” rating and set a $52.00 price objective on shares of FibroGen in a research note on Wednesday, November 9th.

Several large investors have recently bought and sold shares of the stock. Hillhouse Capital Management Ltd. purchased a new stake in FibroGen during the third quarter valued at $10,612,000. Vanguard Group Inc. increased its stake in FibroGen by 8.8% in the second quarter. Vanguard Group Inc. now owns 4,220,201 shares of the biopharmaceutical company’s stock valued at $69,254,000 after buying an additional 339,735 shares during the last quarter. Top Ace Asset Management Ltd purchased a new stake in FibroGen during the third quarter valued at $5,121,000. Candriam Luxembourg S.C.A. increased its stake in FibroGen by 77.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 481,000 shares of the biopharmaceutical company’s stock valued at $9,957,000 after buying an additional 210,000 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in FibroGen by 371.5% in the second quarter. American Century Companies Inc. now owns 230,019 shares of the biopharmaceutical company’s stock valued at $3,775,000 after buying an additional 181,235 shares during the last quarter. 48.23% of the stock is owned by institutional investors and hedge funds.

About FibroGen

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.